Four US drug companies pay $124m for defrauding Medicaid

BMJ 2009; 339 doi: 10.1136/bmj.b4500 (Published 29 October 2009)
Cite this as: BMJ 2009;339:b4500

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. 1New York

    Four US drug companies have made settlements with the US Department of Justice and agreed to pay $124m (£75m; €84m) to resolve false claims that they submitted to the US Medicaid programme after a whistleblower complained.

    The companies were Mylan Pharmaceuticals and UDL Laboratories, which paid $118m; Astra Zeneca, which paid $2.6m; and Ortho McNeil, which paid $3.4m.

    The amount recovered by the US government will be shared between the federal government, the states, the Public Health Service’s drug pricing programme, and the whistleblower.

    “The [US federal] False Claims Act allows a citizen [a whistleblower] to bring fraud to the attention of the government. …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL